NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

APM

Aptorum Group Ltd

Jul 01 • 04:00PM ET

0.9350

Dollar change +0.0250
Percentage change 2.75	%

Healthcare • Biotechnology • United Kingdom • NASD

Peers: ELEV CLRB EDSA INAB CMMB BCAB ATNF NXTC SNTI APVO

| Held by: ONEQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.78	Insider Own	39.73%	Shs Outstand	7.14M	Perf Week	-3.60%
Market Cap	6.68M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.31M	Perf Month	1.63%
Enterprise Value	-0.12M	PEG	-	EPS next Q	-	Inst Own	6.69%	Short Float	1.96%	Perf Quarter	11.31%
Income	-4.27M	P/S	-	EPS this Y	-	Inst Trans	-78.50%	Short Ratio	1.01	Perf Half Y	8.71%
Sales	0.00M	P/B	0.25	EPS next Y	-	ROA	-23.21%	Short Interest	0.08M	Perf YTD	-66.61%
Book/sh	3.77	P/C	7.68	EPS next 5Y	-	ROE	-18.56%	52W High	7.49 -87.52%	Perf Year	-80.40%
Cash/sh	0.12	P/FCF	-	EPS past 3/5Y	52.16% 34.40%	ROIC	-20.18%	52W Low	0.46 103.26%	Perf 3Y	-92.08%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.74% 10.77%	Perf 5Y	-97.61%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	13.91%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.22	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	43.50	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.22	EPS Q/Q	-156.34%	SMA20	-11.00%	Beta	-0.34	Target Price	80.00
Payout	-	Debt/Eq	0.16	Sales Q/Q	-	SMA50	-4.04%	Rel Volume	0.13	Prev Close	0.91
Employees	1	LT Debt/Eq	0.00	Earnings	-	SMA200	-20.30%	Avg Volume	83.90K	Price	0.94
IPO	Dec 18, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	10,704	Change	2.75%

Apr-16-25 12:27PM	Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) -15.28%
Jan-08-25 06:28AM	Aptorum Group to Issue 1.5 Million Class A Shares (TipRanks) -10.63%
Jan-02-25 10:55AM	Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering (GlobeNewswire) -21.43%
Dec-31-24 10:17AM	Why Aptorum Group (APM) Jumped Nearly 300% at Pre-Market Trading (Insider Monkey) +106.64%
Dec-20-24 04:00PM	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024 (Business Wire)
09:15AM	Loading…
Apr-30-24 09:15AM	Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update (Business Wire) +7.58%
Apr-12-24 06:40AM	7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 (InvestorPlace)
Mar-06-24 08:00AM	Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business (Business Wire) +554.44%
Dec-22-23 04:30PM	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023 (Business Wire) +10.95%
Dec-21-23 04:30PM	Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders (Business Wire) +8.96%
Nov-16-23 11:00AM	Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023 (Business Wire)
Aug-10-23 02:57AM	Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets (Business Wire)
Aug-05-23 02:53PM	10 Oversold Global Stocks To Buy (Insider Monkey)
Jun-22-23 08:00AM	Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma (Business Wire)
Jun-09-23 04:30PM	Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris (Business Wire)
04:31PM	Loading…
May-05-23 04:31PM	Aptorum Group Receives Nasdaq Notification of Minimum Stockholders Equity Deficiency (Business Wire) +11.23% -31.96%
May-01-23 08:00AM	Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Groups Subsidiary Paths Innovations Limited (Business Wire) +5.53%
06:10AM	Aptorum Group Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Apr-28-23 09:44AM	Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update (Business Wire) -10.92%
Mar-27-23 07:00AM	Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group (Business Wire) +9.66%
Mar-17-23 08:15AM	Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE)
Mar-03-23 07:30AM	Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus (Business Wire)
07:30AM	Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma (Business Wire)
Mar-02-23 07:30AM	Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China (Business Wire) +10.12%
Feb-10-23 04:30PM	Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency (Business Wire) -6.25% +7.78%
Feb-06-23 10:08AM	Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023 (Business Wire) -11.54%
Jan-23-23 06:49AM	Owning 74% in Aptorum Group Limited (NASDAQ:APM) means that insiders are heavily invested in the company's future (Simply Wall St.)
Jan-20-23 08:00AM	Aptorum Group Announces 1-for-10 Reverse Stock Split (Business Wire)
Jan-04-23 09:00AM	Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms (Business Wire) +7.82%
Dec-22-22 08:00AM	Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders (Business Wire) +7.31%
08:00AM	Loading…
Dec-16-22 08:00AM	Aptorum Group Announces Completion of $3 Million Convertible Note due 2023 (Business Wire) +6.38%
Dec-09-22 07:00AM	Aptorum Group Announces Offering of $3 Million Convertible Note due 2023 (Business Wire)
Nov-25-22 08:30AM	Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE)
08:00AM	Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG) (Business Wire)
Nov-18-22 05:30PM	Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency (Business Wire)
Nov-08-22 06:00AM	Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022 (Business Wire) +5.89%
Oct-07-22 03:40PM	HC Wainwright Initiates Aptorum On Upcoming "Innovative Pipeline" (Benzinga)
Sep-30-22 07:42PM	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022 (Business Wire) -7.26%
Sep-23-22 08:00AM	Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE)
Sep-15-22 11:58AM	Aptorum Highlights Updates On Clinical Validation of RPIDD Infectious Disease Molecular Diagnostics (Benzinga) +5.52%
08:07AM	Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong (Business Wire)
07:00AM	Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics (Business Wire)
Sep-02-22 06:45AM	7 Hot Small-Cap Stocks to Buy in September (InvestorPlace) -6.21%
Aug-25-22 08:31PM	Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022 (Business Wire) -7.79%
Aug-19-22 08:30AM	Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE) -5.49%
Aug-11-22 09:45AM	Aptorum Group (NASDAQ:APM) shareholders are up 12% this past week, but still in the red over the last three years (Simply Wall St.)
May-17-22 08:13AM	Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 26 2022 (Business Wire) +5.71%
May-09-22 11:41AM	Here's Why We're Watching Aptorum Group's (NASDAQ:APM) Cash Burn Situation (Simply Wall St.)
May-02-22 08:00AM	Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma (Business Wire)
Apr-29-22 04:00PM	Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update (Business Wire)
Apr-25-22 09:30AM	First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted (Business Wire) -9.86%
Apr-22-22 08:00AM	Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report® (Business Wire)
Apr-06-22 07:00AM	Andean Precious Metals Announces RSU Grant (Newsfile)
Mar-22-22 05:58PM	Is Andean Precious Metals Corp.'s (CVE:APM) 4.2% ROE Worse Than Average? (Simply Wall St.) -9.27%
Mar-17-22 07:00AM	Andean Precious Metals Reports 2021 Earnings; Delivers on Silver Production and Cost Guidance (Newsfile)
Jan-25-22 10:06AM	SDC Stock Alert: What Has SmileDirectClub Investors Grinning Ear to Ear Today (InvestorPlace) +38.89%
08:21AM	APM Stock Alert: What Is Going on With Little-Known Aptorum Today? (InvestorPlace)
07:45AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jan-20-22 08:47AM	Aptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer (Benzinga) +38.52%
08:00AM	Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma (Business Wire)
Jan-18-22 08:00AM	Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma (Business Wire)
Jan-11-22 04:56AM	Aptorum Group (NASDAQ:APM) investors are sitting on a loss of 90% if they invested three years ago (Simply Wall St.)
Jan-10-22 08:00AM	Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology (Business Wire)
08:00AM	Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers (Business Wire)
08:00AM	Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma (Business Wire)
Dec-03-21 08:00AM	Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders (Business Wire)
Oct-19-21 08:00AM	Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021 (Business Wire) -5.30%
Oct-15-21 08:00AM	Aptorum Group Limited Interview to Air on Bloomberg U.S. (Business Wire)
Sep-15-21 09:26AM	Aptorum To Start Testing SACT-1 In Neuroblastoma Patients (Benzinga) +5.32%
08:00AM	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021 (Business Wire)
08:00AM	Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma (Business Wire)
Aug-03-21 03:01PM	Blue Apron CEO on earnings: What we saw in Q2 was actually very expected (Yahoo Finance Video)
Jul-15-21 02:03AM	What Kind Of Shareholders Hold The Majority In Aptorum Group Limited's (NASDAQ:APM) Shares? (Simply Wall St.)
Jul-12-21 08:59AM	Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate (Benzinga)
08:00AM	Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus (Business Wire)
Jul-09-21 08:00AM	Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report (Business Wire)
Jun-22-21 04:00PM	Commvault Named 2021 HPE GreenLake Momentum Partner of the Year (PR Newswire)
Jun-21-21 08:30AM	GigaOm Radar Reports Name Commvault a "Leader" and "Outperformer" for Hybrid Cloud Data Protection in Enterprise and SMB Categories; Commvault Rated Top Performer Across All Categories in Both Reports (PR Newswire)
May-26-21 08:00AM	Aptorum Group CEO Subscribed Shares In The Company (Business Wire) +5.34%
May-24-21 12:03PM	Verastem's VS-6766/Defactinib Combo Gets Breakthrough Therapy Tag For Ovarian Cancer; BTIG Upgrades Stock (Benzinga) +17.65%
11:57AM	Aptorum's Shares Jump After ALS-4 Targeting Staphylococcus Aureus Shows Encouraging Action In Early-Stage Study (Benzinga)
08:00AM	Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma (Business Wire)
May-13-21 07:00AM	Aptorum Group Limited to Present at The Benzinga Global Small Cap Conference (Business Wire)
May-06-21 07:00AM	Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorums Novel Preclinical Candidate Targeting Womans Gynecological Conditions (Business Wire)
Apr-23-21 11:35AM	Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report. (Business Wire)
Apr-22-21 09:04AM	Aptorum Shares Are Trading Higher On Immunomodulators Agreement For Autoimmune, Oncology Indications (Benzinga)
07:00AM	Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases (Business Wire)
Apr-19-21 07:00AM	Aptorum Group Limited Reports 2020 Fiscal Year End Financial Results and Provides Business Update (Business Wire)
Mar-31-21 07:00AM	Aptorum Group Announces Dosing First Human Subject in a Phase I Clinical Trial of ALS-4, a First-in-Class Small Molecule Drug Designed to Treat Infections caused by Staphylococcus Aureus including Methicillin-resistant Staphylococcus aureus (MRSA) (Business Wire)
Jan-20-21 07:32AM	The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study (Benzinga) +26.42%
06:00AM	Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA) (Business Wire)
Jan-16-21 01:23AM	Could The Aptorum Group Limited (NASDAQ:APM) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Dec-21-20 06:00AM	Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA) (Business Wire)
Dec-10-20 08:00AM	Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders (Business Wire)
Oct-16-20 08:00AM	Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020 (Business Wire)
Oct-02-20 04:05PM	Aptorum Group Announces Closing of $9.0 Million Public Offering (Business Wire) -10.73% +8.91%
Sep-29-20 09:00PM	Aptorum Group Announces Pricing of $9.0 Million Public Offering (Business Wire) +290.16% -43.70%
06:00AM	Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome (Business Wire)
Sep-08-20 03:00AM	Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10 (Business Wire)
02:00AM	Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance (Business Wire)

Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop drug molecules and certain technologies for the treatment and diagnosis of human disease conditions. The Non-Therapeutics segment encompasses diagnostics projects including a novel molecular-based rapid pathogen identification and detection diagnostics, AML Clinic, and sale of natural supplements. Its pipeline include Smart-Act, Acticule, RPIDD, Nativus, and Claves series. The company was founded by Ian Huen on September 13, 2010 and is headquartered in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APM

Aptorum Group Ltd

Upgrade your FINVIZ experience